Pseudoporphyria associated with hemodialysis treated with N-acetylcysteine*
Authors:
- Jean-François TremblayJTJean-François Tremblay
- Bertrand VeilleuxBVBertrand Veilleux
- 1 December 2003
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 49 (6) , 1189-1190
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- PseudoporphyriaJournal of the American Academy of Dermatology, 2001
- Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patientsCardiovascular Research, 2000
- Treatment of haemodialysis-associated pseudoporphyria with N-acetylcysteine: report of two casesBritish Journal of Dermatology, 2000
- Porphyria cutanea tarda in a human immunodeficiency virus‐infected patient: treatment with N‐acetyl‐cysteineInternational Journal of Dermatology, 1998
- Pseudoporphyria cutanea tarda Induced by Furosemide in a Patient Undergoing Peritoneal DialysisDermatology, 1998
- Glutathione antioxidant system as a marker of oxidative stress in chronic renal failureFree Radical Biology and Medicine, 1996
- Pseudoporphyria cutanea tarda: Two case reports on children receiving peritoneal dialysis and erythropoietin therapyThe Journal of Pediatrics, 1992
- Efficacy of Oral N-Acetylcysteine in the Treatment of Acetaminophen OverdoseNew England Journal of Medicine, 1988
- In vivo effects of N-acetylcysteine on glutathione metabolism and on the biotransformation of carcinogenic and/or mutagenic compoundsCarcinogenesis, 1985
- Bullous dermatosis of chronic renal failureBritish Journal of Dermatology, 1976